LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay

References

• NatoliC, PerrucciB, PerrottiF, FalchiL, IacobelliS. Tyrosine kinase inhibitors. Curr Cancer Drug Targets. 2010;10:462–483. doi:10.2174/15680091079151720820384577
   PubMed Web of Science ®Google Scholar
• LemmonMA, SchlessingerJ. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–1134. doi:10.1016/j.cell.2010.06.01120602996
   PubMed Web of Science ®Google Scholar
• Özvegy-LaczkaC, CserepesJ, ElkindNB, SarkadiB. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Updat. 2005;8:15–26. doi:10.1016/j.drup.2005.02.00215939339
   PubMed Web of Science ®Google Scholar
• SteeghsN, NortierJW, GelderblomH. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol. 2007;14:942–953.17103252
   PubMed Web of Science ®Google Scholar
• ImA, SehgalA, CarrollM, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014;28:1774–1783. doi:10.1038/leu.2014.12424699305
   PubMed Web of Science ®Google Scholar
• GarciaJS, StoneRM. The development of FLT3 inhibitors in acute myeloid leukemia. Hematol Oncol Clin. 2017;31:663–680. doi:10.1016/j.hoc.2017.03.002
   PubMed Web of Science ®Google Scholar
• ChengY, PazK. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. IDrugs. 2008;11:46–56.18175263
   PubMed Web of Science ®Google Scholar
• SchittenhelmMM, KampaKM, YeeKW, HeinrichMC. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle. 2009;8:2621–2630. doi:10.4161/cc.8.16.935519625780
   PubMed Web of Science ®Google Scholar
• HaqueA, BanikNL, RaySK. Progress in Molecular Biology and Translational Science. Elsevier; 2011:187–234.
   Google Scholar
• OdiaY, SulJ, ShihJH, et al. A phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma. CNS Oncol. 2016;5:59–67. doi:10.2217/cns-2015-001026860632
   PubMedGoogle Scholar
• YuanT, QiB, JiangZ, et al. Dual FLT3 inhibitors: against the drug resistance of acute myeloid leukemia in recent decade. Eur J Med Chem. 2019;178:468–483. doi:10.1016/j.ejmech.2019.06.00231207462
   PubMed Web of Science ®Google Scholar
• RowlandM, BenetLZ, GrahamGG. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1973;1:123–136. doi:10.1007/bf010596264764426
   PubMedGoogle Scholar
• WilkinsonGR, ShandDG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18:377–390. doi:10.1002/cpt19751843771164821
   PubMed Web of Science ®Google Scholar
• HoustonJB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 1994;47:1469–1479. doi:10.1016/0006-2952(94)90520-78185657
   PubMed Web of Science ®Google Scholar
• ObachRS, BaxterJG, ListonTE, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 1997;283:46–58.9336307
   PubMed Web of Science ®Google Scholar
• BaranczewskiP, StańczakA, SundbergK, et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep. 2006;58:453–472.16963792
   PubMed Web of Science ®Google Scholar
• DarwishHW, AttwaMW, KadiAA. Rapid validated liquid chromatographic method coupled with Tandem mass spectrometry for quantification of nintedanib in human plasma. Trop J Pharm Res. 2016;15:2467–2473. doi:10.4314/tjpr.v15i11.23
   Web of Science ®Google Scholar
• DarwishHW, KadiAA, AttwaMW, AlmutairiHS. Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry. Clinica Chimica Acta. 2018;480:180–185. doi:10.1016/j.cca.2018.02.016
   PubMed Web of Science ®Google Scholar
• AttwaMW, KadiAA, DarwishHW, AmerSM, AlrabiahH. A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: application to metabolic stability investigation and excretion rate. Eur J Mass Spectrom. 2018;24:344–351. doi:10.1177/1469066718768327
   PubMed Web of Science ®Google Scholar
• AmerSM, KadiAA, DarwishHW, AttwaMW. Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation. Chem Cent J. 2017;11:45. doi:10.1186/s13065-017-0274-429086823
   PubMedGoogle Scholar
• J YangJ, N MiltonM, YuS, et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett. 2010;4:202–212. doi:10.2174/187231210792928279
   Google Scholar
• TyzackJD, KirchmairJ. Computational methods and tools to predict cytochrome P450 metabolism for drug discovery. Chem Biol Drug Des. 2019;93:377–386. doi:10.1111/cbdd.1344530471192
   PubMed Web of Science ®Google Scholar
• AttwaMW, KadiAA, AbdelhameedAS, AlhazmiHA. Metabolic stability assessment of new PARP inhibitor talazoparib using validated LC–MS/MS methodology: in silico metabolic vulnerability and toxicity studies. Drug Des Devel Ther. 2020;14:783. doi:10.2147/DDDT.S239458
   PubMed Web of Science ®Google Scholar
• AttwaMW, KadiAA, AbdelhameedAS. Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites. RSC Adv. 2020;10:5412–5427. doi:10.1039/C9RA09115G
   PubMed Web of Science ®Google Scholar
• AlsubiTA, AttwaMW, BakheitAH, DarwishHW, AbuelizzHA, KadiAA. In silico and in vitro metabolism of ribociclib: a mass spectrometric approach to bioactivation pathway elucidation and metabolite profiling. RSC Adv. 2020;10:22668–22683. doi:10.1039/D0RA01624A
   PubMed Web of Science ®Google Scholar
• KadiAA, AbdelhameedAS, DarwishHW, AttwaMW, Al‐ShakliahNS. A highly efficient and sensitive LC‐MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study. Biomed Chromatogr. 2016;30:1248–1255. doi:10.1002/bmc.367426683307
   PubMed Web of Science ®Google Scholar
• AttwaMW, KadiAA, AbdelhameedAS. Reactive intermediates and bioactivation pathways characterization of avitinib by LC–MS/MS: in vitro metabolic investigation. J Pharm Biomed Anal. 2019;164:659–667. doi:10.1016/j.jpba.2018.11.03330472584
   PubMed Web of Science ®Google Scholar
• AttwaMW, KadiAA, DarwishHW, AmerSM, Al-ShakliahNS. Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC-ESI-MS/MS. Chem Cent J. 2018;12:99. doi:10.1186/s13065-018-0467-530251155
   PubMedGoogle Scholar
• AbdelhameedAS, AttwaMW, KadiAA. An LC–MS/MS method for rapid and sensitive high‐throughput simultaneous determination of various protein kinase inhibitors in human plasma. Biomed Chromatogr. 2017;31:e3793. doi:10.1002/bmc.3793
   Web of Science ®Google Scholar
• AlRabiahH, KadiAA, AljoharHI, et al. A new validated HPLC-MS/MS method for quantification and pharmacokinetic evaluation of dovitinib, a multi-kinase inhibitor, in mouse plasma. Drug Des Devel Ther. 2020;14:407–415. doi:10.2147/DDDT.S223573
   PubMed Web of Science ®Google Scholar
• AttwaMW, KadiAA, AbdelhameedAS. Detection and characterization of olmutinib reactive metabolites by LC–MS/MS: elucidation of bioactivation pathways. J Sep Sci. 2020;43:708–718. doi:10.1002/jssc.20190081831788977
   PubMed Web of Science ®Google Scholar
• AttwaMW, DarwishHW, AlhazmiHA, KadiAA. Investigation of metabolic degradation of new ALK inhibitor: entrectinib by LC-MS/MS. Clinica Chimica Acta. 2018;485:298–304. doi:10.1016/j.cca.2018.07.009
   PubMed Web of Science ®Google Scholar
• DaviesB, MorrisT. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093–1095. doi:10.1023/a:10189436131228378254
   PubMed Web of Science ®Google Scholar
• BarterZE, BaylissMK, BeaunePH, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab. 2007;8:33–45. doi:10.2174/13892000777931505317266522
   PubMed Web of Science ®Google Scholar
• IwatsuboT, SuzukiH, SugiyamaY. Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. J Pharmacol Exp Ther. 1997;283:462–469.9353358
   PubMed Web of Science ®Google Scholar
• Health, U. D. o, Services, H. Bioanalytical method validation, guidance for industry. 2001 Available from: http://www. fda. gov./cder/guidance/4252fnl. htm.
   Google Scholar
• KadianN, RajuKSR, RashidM, MalikMY, TanejaI, WahajuddinM. Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry. J Pharm Biomed Anal. 2016;126:83–97. doi:10.1016/j.jpba.2016.03.05227179186
   PubMed Web of Science ®Google Scholar
• ScottWJ, HentemannMF, RowleyRB, et al. Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: identification of copanlisib (BAY 80-6946). ChemMedChem. 2016;11:1517–1530. doi:10.1002/cmdc.20160014827310202
   PubMed Web of Science ®Google Scholar
• AttwaMW, KadiAA, DarwishHW, AbdelhameedAS. Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma. RSC Adv. 2018;8:40387–40394. doi:10.1039/C8RA08161A
   PubMed Web of Science ®Google Scholar
• KadiAA, DarwishHW, AttwaMW, AmerSM. Validated LC-MS/MS method for the quantification of ponatinib in Plasma: application to metabolic stability. PLoS One. 2016;11:e0164967. doi:10.1371/journal.pone.016496727764191
   PubMed Web of Science ®Google Scholar
• DammaccoF, SilvestrisF, editors. Oncogenomics. Academic Press; 2019:477–486.
   Google Scholar
• LeahyDE. Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol. 2006;2:619–628. doi:10.1517/17425255.2.4.61916859409
   PubMed Web of Science ®Google Scholar